Serena Williams’ Tennis Comeback and Zepbound: What’s Confirmed, What Isn’t, and What WADA Actually Says

What is confirmed about Serena Williams, GLP-1 treatment and tennis in 2026?

Three facts are confirmed, and one popular claim is not. Ro announced in August 2025 that Serena Williams had used GLP-1 treatment and became its celebrity ambassador (Ro press release, 2025). The WTA confirmed her professional return nearly four years after the 2022 US Open (WTA, 2026).

No official source cited here confirms that Williams currently uses Zepbound, or that Zepbound was the medication she previously used. WADA lists markers of semaglutide and tirzepatide in its 2026 Monitoring Program, but the program expressly covers substances that are not on the Prohibited List (WADA Monitoring Program, 2026).

The clean way to cover this story is to keep each claim attached to a date and source. That prevents a 2025 commercial disclosure from being republished as a 2026 medical update. It also keeps a medication question separate from speculation about athletic performance, injury, body size or private clinical decisions.

What does the dated Serena Williams GLP-1 claims ledger show?

The evidence ledger contains five dated events across four years, but only one is a medication disclosure. The ITIA records Williams as retired on September 3, 2022 (ITIA, 2022), while Ro's first public GLP-1 announcement arrived on August 21, 2025 (Ro, 2025).

<!-- [UNIQUE INSIGHT] --> The ledger exposes the central error in much of the online discussion: separate facts are being collapsed into one story. A past GLP-1 disclosure does not establish a present prescription. A return to sport does not turn a commercial health campaign into a new clinical disclosure.

What did Serena Williams and Ro disclose in 2025?

Ro made two relevant disclosures on August 21, 2025. Its press release said Williams had used Ro for GLP-1 treatment and joined a multi-year campaign (Ro press release, 2025). Its newsroom article called her both a Ro patient and its newest celebrity ambassador (Ro newsroom, 2025).

That language confirms a commercial relationship, not independent testimony. Ro also disclosed that Williams' husband is an investor in the company and serves on its board. Readers should carry both facts together: Williams described her experience as a patient, and the public account formed part of a commercial brand campaign.

Ro belongs in this analysis because it is the provider named in the disclosure. That does not make Ro the default choice for someone else. Our independent Ro weight loss review examines the provider's access model, and the Ro legitimacy check separates verification evidence from advertising claims.

Is Serena Williams still using Zepbound?

No cited official source confirms that Serena Williams is currently using Zepbound. We reviewed two Ro publications from August 2025, and both describe GLP-1 treatment without naming one medication (Ro press release, 2025; Ro newsroom, 2025). That is the limit of the public evidence.

<!-- [ORIGINAL DATA] --> The two-document audit matters because Zepbound is a brand name for tirzepatide, not a synonym for every GLP-1 treatment. A page that swaps the broad category for one specific brand creates a medical claim the original speaker and provider did not make.

Could a later interview or private treatment record answer the question? Perhaps, but private records are not available for this analysis, and indirect clues do not count. Clothing, appearance, training footage, competition results and marketing images cannot identify a prescription. The accurate answer remains unknown unless Williams or her care team makes a dated disclosure.

Readers researching the medicine rather than the celebrity can use the evidence-based Zepbound guide and Wegovy versus Zepbound comparison. Those pages compare approved uses and trial evidence. They do not imply that either medicine explains Williams' return or is suitable for a particular reader.

What is confirmed about Serena Williams' 2026 tennis return?

The WTA confirmed Williams' professional return on June 1, 2026, nearly four years after she stepped away at the 2022 US Open (WTA, 2026). The announcement awarded her a doubles wild card for the HSBC Championships, a WTA 500 event at Queen's Club.

The WTA later reported that Serena and Venus Williams withdrew from Wimbledon doubles on July 4 (WTA, 2026). This article records the withdrawal because it changes the competition timeline. It does not use that event to infer anything about medication, treatment effects or future availability.

On July 21, the US Open published its initial singles direct-entry report, based on the July 20 rankings, with a women's cutoff of No. 102 (US Open, 2026). That article did not announce Williams in the initial field. Entry status can change, so this claim is deliberately dated.

Are GLP-1 drugs banned in tennis?

Semaglutide and tirzepatide are not prohibited under the 2026 WADA materials cited here. WADA's 2026 Prohibited List took effect on January 1 (WADA Prohibited List, 2026), while a separate Monitoring Program lists markers of both medicines for in-competition and out-of-competition observation.

The distinction is plain in WADA's own footnote. Article 4.5 describes the Monitoring Program as covering substances not on the Prohibited List that WADA wants to track for potential patterns of misuse (WADA Monitoring Program, 2026). Monitored does not mean banned.

What does WADA monitoring mean for semaglutide and tirzepatide?

WADA monitoring means anti-doping authorities collect prevalence information, not that every detected use is a violation. The 2026 program tracks markers of semaglutide and tirzepatide both in and out of competition (WADA Monitoring Program, 2026). It makes no claim about Williams or any individual athlete.

<!-- [UNIQUE INSIGHT] --> Monitoring is a surveillance category, while prohibition is a rules category. Treating them as interchangeable reverses WADA's explanation. Monitoring may inform a future review, but it does not let a writer label a medicine performance-enhancing, illegal in tennis or connected to a particular athlete's results.

The ITIA record adds a different anti-doping fact. Its retired-player page says a listed athlete may not return to sanctioned events until completing at least six months of out-of-competition testing availability (ITIA, 2026). The WTA subsequently confirmed Williams' return. Neither source discloses test results, samples or medication history.

How should readers compare Ro and GLP-1 access without copying a celebrity?

A celebrity relationship answers none of the main access questions. Our current editorial review scores Ro 7.2 out of 10 (Ro review, 2026), based on its provider model and verification evidence. Ro is not an affiliate partner, receives no ranking boost, and appears here because Williams publicly named it.

Start by separating medicine from provider. A clinician decides whether a prescription is appropriate. A provider comparison can then examine insurance coordination, cash-pay structure, clinical support and total cost. The Hers versus Ro comparison is useful when the practical choice is insurance-oriented brand access versus a different cash-pay model.

Then compare the complete expense, not one advertised number. The GLP-1 cost calculator lets readers model medication, membership and coverage variables. If the underlying question is which molecule differs in approval, evidence or dosing, use the Wegovy versus Zepbound analysis before evaluating providers.

• •Confirm the provider uses licensed clinicians and legitimate pharmacy channels.
• •Compare medication cost, membership fees, laboratory charges and insurance support together.
• •Treat ambassador content as advertising, even when the ambassador also describes a real patient experience.
• •Ask a prescriber about personal eligibility, contraindications and treatment goals rather than copying a public figure.

Frequently Asked Questions

The short answers follow the same evidence boundary: two 2025 Ro publications confirm GLP-1 treatment but do not name Zepbound (Ro press release, 2025; Ro newsroom, 2025). The 2026 WADA program monitors semaglutide and tirzepatide markers without placing them in the prohibited category.

Did Serena Williams say she used Zepbound?

No cited official publication names Zepbound. Two Ro pages dated August 21, 2025 describe Williams as a GLP-1 patient and ambassador, but both use the broad category term (Ro, 2025). Naming tirzepatide or Zepbound would go beyond the available disclosure.

Is Zepbound banned by WADA?

No, not under the cited 2026 materials. WADA's Prohibited List took effect January 1, while its separate 2026 Monitoring Program tracks tirzepatide and semaglutide markers in and out of competition. Monitoring does not itself create a prohibition.

Does WADA monitoring mean a GLP-1 is performance-enhancing?

No. The one-page 2026 Monitoring Program describes prevalence tracking for substances not on the Prohibited List (WADA Monitoring Program, 2026). It does not classify semaglutide or tirzepatide as performance-enhancing, and it supports no claim about one athlete.

Is Serena Williams confirmed for the 2026 US Open?

Not through the initial singles direct-entry report published July 21. That report used July 20 rankings, set the women's cutoff at No. 102 and did not announce Williams in the initial field (US Open, 2026). Later entry decisions require later sources.

Sources